You must be a current COE Member and logged into your account to view this content.
Don’t have an account? Sign up.
You must be a current COE Member and logged into your account to view this content.
Don’t have an account? Sign up.
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | No |
| Comments | Biopsy is not performed at our facility. |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Cyndi Lemery |
| Title | Director of Lung Cancer Screening |
| clemery@ccihsv.com | |
| Phone | (256)-653-8143 |
| User ID | Cyndi Lemery |
| Facility ID | 1018 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | No |
| Comments | We do have a referral pathway and collaborate well with the thoracic oncology team at the local hospitals. |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | No |
| Comments | We do have a referral pathway and collaborate well with the pathology team at the local hospitals. |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Comments | ACR Registry as well as Tumor Registry at the hospital. Clearview Cancer Insitute participates in many clinical trials. |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 8 |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | No |
| Comments | We do not have thoracic oncologists/surgeons on site. We do work closely with outside hospitals. |
| Name | Cyndi Lemery |
| Title | Director of Lung Cancer Screening |
| clemery@ccihsv.com | |
| Phone | (256)-653-8143 |
| User ID | Cyndi Lemery |
| Facility ID | 1018 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | No |
| Comments | Biopsy is not performed at our facility. |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Cyndi Lemery |
| Title | Director of Lung Cancer Screening |
| clemery@ccihsv.com | |
| Phone | (256)-653-8143 |
| User ID | Cyndi Lemery |
| Facility ID | 1018 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Brandon Koehler |
| Title | Lung Cancer Program Manager |
| brandon.koehler@nmhs.org | |
| Phone | (402)-354-8337 |
| User ID | Brandon Koehler |
| Facility ID | 1029 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Brandon Koehler |
| Title | Lung Cancer Program Manager |
| brandon.koehler@nmhs.org | |
| Phone | (402)-354-8337 |
| User ID | Brandon Koehler |
| Facility ID | 1029 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Comments | This is the primary responsibility of ordering provider and attestation is required prior to scheduling. Future plans include adding tobacco treatment support at the time of screening as well. |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Comments | Yes, this is not an elaborate system. However, I look forward to direction from Go2 for improving our current system. |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Stephonie Zwald |
| Title | Oncology Nurse Navigator |
| stephonie.zwald@stjoe.org | |
| Phone | (707)-445-8121 |
| User ID | Stephonie Zwald |
| Facility ID | 1020 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Cyndi Lemery |
| Title | Director of Lung Cancer Screening |
| clemery@ccihsv.com | |
| Phone | (256)-653-8143 |
| User ID | Cyndi Lemery |
| Facility ID | 1018 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Janakiraman Subramanian |
| Title | MD |
| janakiraman.subramanian@inova.org | |
| Phone | (571)-472-0250 |
| User ID | Kimberly Pullen |
| Facility ID | 1017 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Melissa Morrison |
| Title | Manager, NHCI Clinical Programs |
| Melissa.morrison@northside.com | |
| Phone | (404)-252-5679 |
| User ID | Deb Jeskey |
| Facility ID | 1009 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Deb Jeskey |
| Title | Lung & GU/Prostate Oncology Program Coordinator |
| deborah.jeskey@northside.com | |
| Phone | (404)-300-2688 |
| User ID | Deb Jeskey |
| Facility ID | 1009 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Comments | yes - we are trying to improve on our reporting metrics |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Comments | Yes. In 2024 we have been working with ACS in a QI project |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Comments | this is a goal |
| Name | Michael Mair |
| Title | RN |
| Michael.Mair@dignityhealth.org | |
| Phone | (916)-962-8864 |
| User ID | Michael Mair |
| Facility ID | 1016 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Amit Mahajan |
| Title | MD |
| amit.mahajan@inova.org | |
| Phone | (571)-472-1380 |
| User ID | Kimberly Pullen |
| Facility ID | 1017 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Amit Mahajan |
| Title | MD |
| amit.mahajan@inova.org | |
| Phone | (571)-472-1380 |
| User ID | Kimberly Pullen |
| Facility ID | 1017 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Dr. Keith Mortman |
| Title | Thoracic Surgeon |
| kmortman@mfa.gwu.edu | |
| Phone | (202)-677-6197 |
| User ID | Patricia Rizk |
| Facility ID | 1008 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amit Mahajan |
| Title | MD |
| amit.mahajan@inova.org | |
| Phone | (571)-472-1380 |
| User ID | Kimberly Pullen |
| Facility ID | 1017 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Amit Mahajan |
| Title | MD |
| amit.mahajan@inova.org | |
| Phone | (571)-472-1380 |
| User ID | Kimberly Pullen |
| Facility ID | 1015 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Rachel McConachie |
| Title | RN, MSN Director of Dignity Health Cancer Insitute |
| Rachel.McConachie@commonspirit.org | |
| Phone | (916)-962-8892 |
| User ID | Michael Mair |
| Facility ID | 1016 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | No |
| Calculated Section Total | 4 |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | No |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Angela Barry |
| Title | vampire slayer |
| abarry@go2.org | |
| Phone | (123)-456-7891 |
| User ID | Angela Barry |
| Facility ID | 2011 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Meg Fay |
| Title | Nurse Mgr |
| mfay@go2.org | |
| Phone | (502)-682-7745 |
| User ID | Angela Barry |
| Facility ID | 2011 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Robin Mohon |
| Title | Contact Person |
| rmohon@go2.org | |
| Phone | (123)-456-7891 |
| User ID | Angela Barry |
| Facility ID | 2011 |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | Yes |
| Calculated Section Total | 5 |
| Qualification Status | Qualified |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | Yes |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Robin Mohon |
| Title | Coordinator |
| rmohon@go2.org | |
| Phone | (270)-996-8533 |
| User ID | Robin Mohon |
| Facility ID | 2014 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | No |
| Comments | This is in progress and should be completed by 1st quarter of 2025 |
| Calculated Section Total | 6 |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Robin Mohon |
| Title | Coordinator |
| rmohon@go2.org | |
| Phone | (270)-996-8533 |
| User ID | Robin Mohon |
| Facility ID | 2014 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Robin Mohon |
| Title | Coordinator |
| rmohon@go2.org | |
| Phone | (270)-996-8533 |
| User ID | Robin Mohon |
| Facility ID | 2014 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | No |
| Comments | This is in progress and should be completed by 1st quarter of 2025 |
| Calculated Section Total | 6 |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Robin Mohon |
| Title | Coordinator |
| rmohon@go2.org | |
| Phone | (270)-996-8533 |
| User ID | Robin Mohon |
| Facility ID | 2014 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Robin Mohon |
| Title | Coordinator |
| rmohon@go2.org | |
| Phone | (270)-996-8533 |
| User ID | Robin Mohon |
| Facility ID | 2014 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | Yes |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Calculated Section Total | 7 |
| Qualification Status | Qualified |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | Yes |
| Name | Jeremy Bentham |
| Title | IPN Guy |
| jipnguy@intula.com | |
| Phone | (972)-555-6161 |
| User ID | Jeremy Bentham |
| Facility ID | 1007 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | No |
| Internal clinical outcomes review and quality improvement process. | No |
| Calculated Section Total | 5 |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | No |
| Name | Angela Barry |
| Title | dog catcher |
| abarry@go2.org | |
| Phone | (202)-774-5389 |
| User ID | Angela Barry |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | No |
| Name | Angela Barry |
| Title | smooth operator |
| abarry@go2.org | |
| Phone | (202)-774-5389 |
| User ID | Angela Barry |
| Facility ID | 2010 |
| Structured nodule reporting in place for standardized follow-up and management decisions based on appropriate and established nodule classification systems and management guidelines. | Yes |
|---|---|
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning findings. | Yes |
| Commitment to a standardized process for communication with patients and their active care providers about test results and management plan. | Yes |
| Ask about current smoking status and advise to quit. Provide or refer for cessation services. | Yes |
| Adherence to standards based on published best practices for controlling image quality, as low as reasonably achievable radiation dose, and diagnostic procedures as outlined by the American College of Radiology. | Yes |
| Tracking, measuring, and reconciliation process for interval follow-up adherence for incidentally detected lung nodules based on patient risk for lung cancer and surveillance guidelines. | No |
| Internal clinical outcomes review and quality improvement process. | No |
| Calculated Section Total | 5 |
| Institutional workflows that capture (at all entry points into the health system) and refer incidental pulmonary nodules for management. | Yes |
| Institutional tools are engaged to ensure all IPNs are identifed and managed. | No |
| Name | Angela Barry |
| Title | dog catcher |
| abarry@go2.org | |
| Phone | (202)-774-5389 |
| User ID | Angela Barry |
| Access to guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline eligible tumors (when clinically appropriate) to determine eligibility for targeted therapies or immunotherapies. | Yes |
|---|---|
| Biomarker and PD-L1 results are reviewed and discussed with patients once results are available. Discussion includes the clinical implications and therapeutic options based on these results. | Yes |
| When appropriate, guideline directed PD-L1 and biomarker testing are integrated into treatment decisions before systemic therapy is initiated. | Yes |
| In the setting of disease progression on FDA approved therapy, updated PD-L1 and biomarker testing is utilized to identify next therapeutic option. | Yes |
| In the setting of disease progression, updated PD-L1 and biomarker testing is utilized to confirm need for clinical trial referral when FDA approved therapeutics are not an option. | No |
| Calculated Section Total | 4 |
| Rapid on-site evaluation (ROSE), when available to increase diagnostic and molecular yield. | No |
| Utilization of liquid biopsy modalities in the setting of tissue insufficiency or unavailability and points of disease progression. | Yes |
| Name | Angela Barry |
| Title | bottle washer |
| abarry@go2.org | |
| Phone | (202)-774-5389 |
| User ID | Angela Barry |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | No |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Angela Barry |
| Title | lackey |
| abarry@go2.org | |
| Phone | (202)-774-5389 |
| User ID | Angela Barry |
| Facility ID | 2010 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Joe |
| Title | RN |
| mfay@go2.org | |
| Phone | (202)-867-5309 |
| User ID | Meg Fay |
| Facility ID | 2017 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | No |
| Comments | We do not yet have an MDT |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 8 |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | No |
| Name | Joe |
| Title | RN |
| mfay@go2.org | |
| Phone | (202)-867-5309 |
| User ID | Meg Fay |
| Facility ID | 2015 |
| A patient-centered discussion about the potential benefits and harms of lung cancer treatment occurs at each point of the patient’s cancer care journey. | Yes |
|---|---|
| Biomarker Testing: Access to and compliance with guideline-directed testing for molecular and immune biomarkers with NGS technology in all patients with guideline-eligible tumors (when clinically appropriate). Using NGS results, consistently identify actionable mutations and eligiblity for guideline-directed targeted therapies or immunotherapies. | Yes |
| Medical Oncology: Compliance with practice standards for the diagnostic workup, staging, and medical oncology (disease specific) treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Radiation Oncology: Compliance with practice standards for the diagnostic workup, staging, and radiation treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Thoracic Oncology: Compliance with practice standards for the diagnostic workup, staging, and surgical treatment of all lung cancer types based on evidence, expert consensus, and practice guidelines for cancer care and treatment. | Yes |
| Pathology: Comply with practice standards based on evidence, expert consensus, and practice guidelines for pathologic evaluation of malignancies. | Yes |
| Actively engage or have access to multidisciplinary expert input by way of tumor board or other team-based mechanism, including virtual. | Yes |
| Commitment and care delivery mechanisms are in place that standardizes consistent communication with patients and their active care providers about test results, diagnostic workup, and management plan. | Yes |
| Contribute to aggregated collection of relevant data and report to a cancer registry. (hospital, central or state, or special purpose registry, NPCR, NCI, SEER) | Yes |
| Comments | here's a comment as well |
| Ask about current smoking status and, as appropriate, advise to quit. Provide or refer for cessation services. | Yes |
| Calculated Section Total | 10 |
| Qualification Status | Qualified |
| Internal clinical outcomes review and quality improvement process. | Yes |
| Thoracic Oncologist(s) are board certified thoracic or cardio-thoracic surgeons. | Yes |
| Name | Jerccprogram Smith |
| Title | CC Program Manager |
| jerccprogmanager@intula.com | |
| Phone | (444)-555-7888 |
| User ID | Jeremy Bentham |
| Facility ID | 1007 |
| Screen according to CMS, NCCN, USPSTF criteria; if your program screens patients outside these established criteria, please identify your process for identifying patients’ screening appropriateness and which additional risk factors are considered for screening eligibility. | Yes |
|---|---|
| A patient-centered discussion (about the benefits and harms) occurs before or at the time of low dose CT screening - for every baseline screening at a minimum. | Yes |
| Adherence to standards based on best-published practices for controlling screening quality, radiation dose and diagnostic procedures as outlined by American College of Radiology Practice Parameters. | Yes |
| Utilize structured reporting and standardized follow-up and management decisions based on current, established screening classification systems and management algorithms (LungRADS, NCCN Clinical Guidelines, I-ELCAP). | Yes |
| Consult with or refer to a lung cancer multidisciplinary* and cancer care team for the management of any concerning (thoracic or extra-thoracic) findings in the screening process. | Yes |
| Comments | here's a comment |
| Integrate a standardized process within the screening workflow for patient and referring provider/care team communication on screening results and management plan. | Yes |
| Provide cessation support to all screening patients with consistent integration of the Ask-Advise-Refer Process: Ask about current smoking status, Advise to quit, Provide or Refer for evidence-based cessation services as appropriate. | Yes |
| Utilize a process for tracking, measuring, and reconciliation of annual and interval follow-up adherence in screening. | Yes |
| Collect and review internal clinical outcomes in a quality improvement process. | Yes |
| Calculated Section Total | 9 |
| Qualification Status | Qualified |
| Submission of LDCT screening data to a multi-site registry (e.g., ACR LCSR, IELCAP, or other). | Yes |
| Monitor for lung cancer stage shift among screen-detected lung cancers. | Yes |
| Name | Jacob Screeningmanager |
| Title | Screening Manager |
| jacobscreeningmanager@intula.com | |
| Phone | (848)-555-1212 |
| User ID | Jeremy Bentham |